focus -WSS

focus

author：leisure time 2025-09-03 03:23:53 - browse：53975

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Activists slam private health insurers over coverage restrictions
Next article： WHO recommends second malaria vaccine

WSS

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

What will Novo Nordisk's VC do with its influx of cash?

Bird flu makes raw milk dangerous to consume, mouse study finds

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Why some fertility treatments produce more boy babies

Hospitals need to get ahead of regulations on climate change

knowledge

focus

explore

How one medical school became remarkably diverse

Why some fertility treatments produce more boy babies

Medical records are filled with copy

Unmasking the 'centricity' illusion in clinical trials

Hollywood unions extend contract negotiations for actors

U.S. death rates show how politics are affecting public health

Apple is now the first public company to be valued at $3 trillion

Experts study whether long Covid risk adds up with each reinfection

Drug repurposing or repositioning? The language matters

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Wikipedia

Nobel honors Karikó and Weissman's enduring partnership

What will Novo Nordisk's VC do with its influx of cash?

Bird flu makes raw milk dangerous to consume, mouse study finds

CRISPR base editing slashes cholesterol levels in monkeys

RSV injection headlines need to be accurate for good uptake

6 solutions to address cancer drug shortages and others

leisure time

focus

leisure time

explore